Arcus Biosciences, Inc.
Arcus Biosciences, Inc. scores highest on Nitro (68) and lowest on Price (12). Its PosiPenta is 41.13 out of 100, around the middle of similar companies.
On the Penta Grid this week, Arcus Biosciences, Inc. is Grid #499 of 836 in the Healthcare sector in United States, and Grid #2,772 of 3,999 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Arcus Biosciences, Inc. | 41.13 | 12 | 27 | 68 | 31 | 68 |
| SELLAS Life Sciences Group, Inc. | 48.58 | 5 | 64 | 71 | 67 | 36 |
| Prestige Consumer Healthcare Inc. | 63.43 | 74 | 71 | 63 | 50 | 60 |
| MBX Biosciences, Inc. | 47.61 | 12 | 20 | 74 | 67 | 65 |
| Celldex Therapeutics, Inc. | 42.26 | 21 | 20 | 57 | 65 | 48 |
| Supernus Pharmaceuticals, Inc. | 52.38 | 27 | 64 | 42 | 66 | 62 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -5.66 |
| P/B ratio | 6.00 |
EEarnings
| Trailing EPS | ₹-370.34 |
| Forward EPS | ₹-299.87 |
NNitro
| Price | 2095.09 |
| 52-week high | 3005.78 |
| 52-week low | 1519.23 |
| Fall from 52-week high | 30.3% |
TTorque
| Return on equity (ROE) | -90.82% |
| Debt-to-equity | 0.51 |
AAnchor
| Beta (price swings) | 0.94 |
| Market cap | ₹26,350 Cr |
| Insider holding | 28.80% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Arcus Biosciences, Inc.'s PosiPenta score?
Arcus Biosciences, Inc.'s PosiPenta is 41.13 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Arcus Biosciences, Inc. stand on the Penta Grid?
On the Penta Grid this week, Arcus Biosciences, Inc. is Grid #499 of 836 in the Healthcare sector in United States, and Grid #2,772 of 3,999 in United States.
Which PosiPenta pillar is strongest for Arcus Biosciences, Inc.?
Nitro (momentum), with a score of 68 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Arcus Biosciences, Inc.?
Price (valuation), with a score of 12 out of 100: much weaker than most similar companies.
Has Arcus Biosciences, Inc.'s PosiPenta changed since last week?
Yes, it rose 13.69 points, from 27.44 to 41.13.
PositoAI is for research and education only and is not investment advice.